| First Author | Ma F | Year | 2025 |
| Journal | Cell Metab | Volume | 37 |
| Issue | 5 | Pages | 1152-1170.e7 |
| PubMed ID | 40015280 | Mgi Jnum | J:379016 |
| Mgi Id | MGI:8168322 | Doi | 10.1016/j.cmet.2025.01.020 |
| Citation | Ma F, et al. (2025) EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis. Cell Metab |
| abstractText | Excess cholesterol accumulation contributes to fibrogenesis in metabolic dysfunction-associated steatohepatitis (MASH), but how hepatic cholesterol metabolism becomes dysregulated in MASH is not completely understood. We show that human fibrotic MASH livers have decreased EH-domain-binding protein 1 (EHBP1), a genome-wide association study (GWAS) locus associated with low-density lipoprotein (LDL) cholesterol, and that EHBP1 loss- and gain-of-function increase and decrease MASH fibrosis in mice, respectively. Mechanistic studies reveal that EHBP1 promotes sortilin-mediated PCSK9 secretion, leading to LDL receptor (LDLR) degradation, decreased LDL uptake, and reduced TAZ, a fibrogenic effector. At a cellular level, EHBP1 deficiency affects the intracellular localization of retromer, a protein complex required for sortilin stabilization. Our therapeutic approach to stabilizing retromer is effective in mitigating MASH fibrosis. Moreover, we show that the tumor necrosis factor alpha (TNF-alpha)/peroxisome proliferator-activated receptor alpha (PPARalpha) pathway suppresses EHBP1 in MASH. These data not only provide mechanistic insights into the role of EHBP1 in cholesterol metabolism and MASH fibrosis but also elucidate an interplay between inflammation and EHBP1-mediated cholesterol metabolism. |
